DNA倍体分析联合HPV分型诊断对宫颈癌筛查的临床价值  

Clinical value of DNA ploidy analysis combined with HPV genotyping in screening of cervical cancer

作　　者：郑柳莎 吴丹艳[2] 全燕[2] 王亚军[2] 

机构地区：[1]十堰市妇幼保健院体检中心,湖北十堰442000 [2]十堰市妇幼保健院妇女保健科,湖北十堰442000

出　　处：《西南国防医药》2017年第9期942-944,共3页Medical Journal of National Defending Forces in Southwest China

摘　　要：目的探究DNA倍体分析联合人乳头瘤病毒(HPV)分型诊断对宫颈癌筛查的临床价值。方法将60例行宫颈癌筛查的患者分别进行DNA倍体分析和HPV分型诊断,以最终病理诊断为标准,比较DNA倍体分析与DNA倍体分析联合HPV分型诊断对宫颈癌筛查的检出率和准确率。结果单一DNA倍体分析与DNA倍体分析联合HPV分型诊断在宫颈癌检出率上无统计学差异(P>0.05),但联合检查在筛查诊断原位癌(CINⅠ~Ⅲ)上的准确率明显高于单一DNA倍体分析(P<0.05)。联合检查共发现阳性病例57例,筛查检出率为95.00%;单一DNA倍体分析仅发现阳性病例48例,筛查检出率为80.00%,两种方法筛查的检出率有显著差异(P<0.05)。结论 DNA倍体分析对宫颈癌早期筛查具有一定的临床诊断价值,通过联合HPV分型诊断,能够提高宫颈癌筛查的准确率,有利于宫颈癌的早期诊断。Objective To explore the clinical value of DNA ploidy analysis combined with HPV genotyping in the screening of cervical cancer. MeAods A total of 60 patients to receive cervical cancer screening received DNA ploidy analysis and HPV genotyping respectively to compare the detection rate and accuracy of cervical cancer screening by DNA ploidy analysis and DNA ploidy analysis combined with HPV genotyping. Results Single DNA ploidy analysis and DNA ploidy analysis combined with HPV genotyping showed no significant difference in the detection rate of cervical cancer （P 〉 0.05）, but the combined examination had higher accuracy in the screening diagnosis of carcinoma in situ （CIN I-III） than single DNA ploidy analysis （J3 〈 0.05）. The combined examination discovered 57 positive cases and the screening detection rate was 95.00%; single DNA ploidy analysis only discovered 48 positive cases and the screening detection rate was 80.00% . The screening detection rate by the two methods showed significant difference （P 〈 0.05）. Conclusion DNA ploidy analysis has certain clinical diagnostic value in the early screening of cervical cancer. The combination with HPV genotyping can improve the accuracy of cervical cancer screening and is beneficial to the early diagnosis of cervical cancer.

关 键 词：宫颈癌 筛查 DNA倍体 HPV分型 

分 类 号：R737[医药卫生—肿瘤]